40 results about "Mucositis" patented technology

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

Provided are Streptococcus salivarius and compositions comprising Streptococcus salivarius for the treatment of ENT diseases, in particular cancer therapy-induced oral mucositis and respiratory tract infections associated with cancer therapy.

Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.

Composition for use for the treatment and / or prevention of infections or lesions of the (oral) mucosa, in particular originating from at least one selected the group consisting of: perleche; scarlet fever; pharyngitis; acute necrotising ulcerative mucositis; impetigo contagiosa; chelitis glandularis apostem atosa; gingivostomatitis herpetica; herpes simplex; herpes stabistis recidivans; herpes zoster; hand-foot-mouth; human papilloma virus; HIV; oral candidiasis; oral lichen planus; lichen ruber planus; leukoplakia, erythroplakia; methicillin-resistant staphylococcus aureus; gingivitis / periodontitis; mucositis / peri- implantitis; alveolar osteolytis; wherein the composition comprises or consists of the following components: (a) polyhexanide (PHMB); (b) an organic or inorganic buffer different from a); (c) further additives; (d) optionally water.

The invention discloses a traditional Chinese medicine composition for treating chemotherapy-related oral mucositis and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix rehmanniae recen, 6-12 parts of radix ophiopogonis, 6-12 parts of radix scrophulariae, 6-12 parts of honeysuckle, 6-12 parts of fructus forsythiae, 3-7 parts of radix scutellariae, 1-3 parts of lotus plumule, 3-7 parts of mint and 3-7 parts of borneol. The composition has the effects of nourishing yin, clearing heat, astringing sores and promoting tissue regeneration, and clinical tests prove that the composition can remarkably reduce the occurrence rate of chemotherapy-related oral mucositis of hematological malignancy patients, relieve the damage degree of oral mucosa, shorten the lasting time of ulcer and pain and effectively improve clinical symptoms of traditional Chinese medicine, and is high in safety.

The invention discloses an effective part for chemoradiotherapy-induced oral mucositis in traditional Chinese medicinal material white flower and a preparation process of the effective part. The effective part is identified as a flavonoid component through standard substance spectrogram comparison. Tests prove that the production process of the effective part is practical and feasible, and the total flavonoids in the finally obtained extracting solution are greater than or equal to 50%. Besides, pharmacodynamic studies show that the effective part has a remarkable bacteriostasis effect on staphylococcus aureus, escherichia coli and candida albicans, the bacteriostasis rate is larger than or equal to 80%, the effective part has a remarkable treatment effect on rat oral mucosa acute inflammation caused by chemoradiotherapy, and the application prospect of the effective part in the adaptation disease is shown.

The invention relates to application of a composition taking taurine as a main active ingredient in preparation of a medicine for promoting mucous membrane healing. Water is used as a solvent, the taurine oral liquid contains 0.1 wt%-40wt% of taurine, 0.01 wt%-1wt% of amino acid, 0.01 wt%-0.5 wt% of vitamin, a protective agent, a bacteriostatic agent, a preservative, a swelling and pain relieving agent and the like. Through verification, the composition disclosed by the invention is prepared into oral spray, fine mist particles of 10-70 microns generated by a spray instrument show a good treatment effect on radiation-induced oral mucositis, and also have a good healing promoting effect on normal oral mucosa tissues after an alveolar surgery.

The invention discloses an oral mucositis prevention gargling device for a patient, and relates to the technical field of medical instruments, the oral mucositis prevention gargling device comprises a liquid storage unit composed of a first cylinder and a second cylinder; the liquid conveying pump is mounted at the inner bottom of the first cylinder body and is connected to the gargling spray head through a liquid conveying pipeline; wherein a sealing disc is arranged in the second cylinder body, and the sealing disc divides the interior of the second cylinder body into an upper functional chamber and a lower negative pressure chamber; the four-way pipe is mounted on a top plate of the second barrel; the negative pressure pump is mounted in the negative pressure cavity and connected to the first connector of the four-way pipe through a negative pressure pipeline; the partition plate is fixed to the top of the sealing disc and divides the functional cavity into a washing cavity on one side and a collecting cavity on the other side, through the designed backwashing device, backwashing can be conducted on a pipeline, accumulated impurities are removed, the pipeline is recovered to be smooth, the blocking risk is reduced, and the continuity of the treatment process is guaranteed.

Peptides and methods of use thereof, are disclosed for use in treating various disease and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The peptides modulate the activity of the transcription factor NF κB.

The invention relates to a compound medicine for treating oral mucositis caused by luconobutuzumab and a preparation method of the compound medicine, and the compound medicine realizes the comprehensive curative effects of resisting inflammation, easing pain and promoting mucosal repair through combination of traditional Chinese medicines and western medicines and synergism of multi-ethnic medicines. The compound medicine is prepared from the following components in parts by weight: 0.1 to 0.5 part of recombinant human epidermal growth factor, 0.5 to 2.0 parts of lidocaine, 0.01 to 0.1 part of vitamin B12, 1.0 to 5.0 parts of astragalus polysaccharide, 0.5 to 3.0 parts of honeysuckle chlorogenic acid, 0.2 to 1.5 parts of glycyrrhizic acid, 0.1 to 1.0 part of crocin, 0.3 to 2.0 parts of saussurea involucrata flavone, 0.2 to 1.8 parts of paris polyphylla saponin and 0.4 to 2.5 parts of sculellaria barbata flavone. The compound provided by the invention is suitable for tumor patients receiving treatment of luconatobutuzumab, is especially suitable for patients suffering from I-III grade oral mucositis, can be used as a hospital preparation or new drug development, and has wide clinical application and market prospects.

The present invention relates to superoxide dismutase, and uses thereof for preventing or treating mucositis. The superoxide dismutase according to the present invention can be effectively used for treating or improving the inhibition of a proliferation of mucous epithelium cells, which is a side effect of anticancer agents or radiotherapy.

The present application relates to a kind of traditional Chinese medicine composition for treating oral mucositis caused by radiotherapy and chemotherapy, the traditional Chinese medicine composition is composed of effective component and medically acceptable auxiliary materials, characterized in that, the effective component is made of the following weight percentage of raw medicinal materials: Shihuchu 33-41%, Shengdi 20-24%, Maidong 20-24%, Shengancao 17-20%.The traditional Chinese medicine composition described in the present application has the effect of benefiting stomach, generating fluid, nourishing yin and clearing heat, and the effect of treating oral mucositis caused by radiotherapy and chemotherapy is remarkable.

The application belongs to the technical field of biological medicine, and discloses a kind of pharmaceutical composition for oral mucositis and preparation method thereof.The pharmaceutical composition is composed of traditional Chinese medicine extract component 55~70wt% and chemical component 30~45wt%, traditional Chinese medicine extract component is composed of white and extract 30~44wt%, Huangqin extract 20~28wt%, Huangqi extract 15~22wt%, Huanglian extract 8~15wt%, borneol 3~5wt%, and chemical component is composed of sodium hyaluronate 25~38wt%, D-panthenol 22~30wt%, allantoin 18~25wt%, dipotassium glycyrrhizinate 15~22wt%.The traditional Chinese medicine extract component in the application follows the compatibility principle of monarch, minister, assistant and messenger, and has integrated treatment effect of anti-inflammatory, repair, pain relief and infection prevention after being matched with chemical component, can significantly reduce the level of inflammation factor of oral mucositis, and significantly shorten the healing time of oral mucositis.

The invention provides an oral mucositis cryotherapy apparatus, and belongs to the technical field of oral mucositis cryotherapy. In order to solve the problems that in the prior art, the cold compress effect is poor, cooling liquid is inconvenient to recycle, and conditions before and after cold compress are difficult to check, the cold compress therapeutic apparatus comprises a therapeutic apparatus body, a storage battery and a control panel, the storage battery and the control panel are arranged in the therapeutic apparatus body, and a button is installed on the upper surface of the control panel. A semiconductor chilling plate is attached to the lower surface of the cooling bin, and a threaded rod is rotationally connected into the therapeutic apparatus body. The oral mucositis cold compress device plays an auxiliary and convenient role in oral mucositis cryotherapy, can be quickly adjusted, and monitors the cold compress temperature and effect during oral mucositis cryotherapy.

A method of treating acne, of treating UV or radiation induced injury, of reducing the appearance of scars, and / or of treating mucositis, including topically applying a composition including CAPE to a human or other mammal in need thereof, in a therapeutically effective amount and / or from about 1% to about 50% CAPE by weight.

This application relates to the field of nanomedicine technology, and in particular to a selenium-containing nanoparticle, its preparation method, and its application in drugs for treating inflammatory mucosal diseases. The selenium-containing nanoparticle has a core comprising zero-valent selenium or ferrous selenide, and a shell comprising at least one of polyserotonin, dopamine, and sodium alginate; the two are bonded together by C-Se covalent bonds to form a stable organic-inorganic nanocomposite. This selenium-containing nanoparticle overcomes the bottlenecks of traditional selenium nanoparticles, such as easy aggregation and poor retention, and achieves synergistic enhancement of antioxidant, anti-inflammatory, and antibacterial functions. When applied to the treatment of inflammatory mucosal diseases, it can effectively treat inflammatory mucosal diseases in complex environments, such as oral mucositis, based on the "seed-soil" synergistic treatment concept, by synergistically regulating the triple mechanism of "epithelial cells (seeds)," "immune microenvironment (soil)," and "local flora."

The invention discloses application of a prognosis nutritional index in preparation of an amitinib-related oral mucositis risk assessment kit, and relates to the technical field of medical diagnosis and risk assessment. The invention provides an application of a prognosis nutritional index in preparation of an amitinib-related oral mucositis risk assessment kit. The prognosis nutrition index is divided into four quartile intervals: Q1 (10.10 to 46.90), Q2 (46.91 to 50.65), Q3 (50.66 to 55.20) and Q4 (55.21 to 320.80). Large sample retrospective analysis proves that the PNI and the amitinib related oral mucositis risk are in significant negative correlation, the OM risk is reduced by about 1% every time the PNI is increased by 1 unit, stability is kept in multi-factor regression, tendency score matching and subgroup analysis, and the risk assessment accuracy is high. The method is high in clinical applicability, low in cost, easy and convenient to operate and suitable for primary hospitals and high-load medical environments, and the PNI is calculated based on conventional blood detection indexes.

The present application relates to the technical field of medical dressings, in particular to an external use gel for preventing oral mucositis caused by chemotherapy, and a preparation method, which adopts a combination of catechol group modified polymers and an acidic anti-crosslinking system, and through the dual inhibition of catechol group oxidation by acidic pH and antioxidants in a brown bottle, the gel is stored as a flowable liquid for a long time, after being sprayed to the oral cavity, the catechol group is triggered to rapidly oxidize and crosslink, forming a solid gel film, which physically protects the oral ulcer site, and cooperates with a heat conduction functional system to greatly improve the heat conduction performance of the gel, enabling the cold quantity of cryotherapy to be uniformly transmitted to the superficial tissue of the oral mucosa, without the need for the tongue to push the ice block to move, thereby reducing the pain of the patient, and solving the problem of uneven cooling of existing cryotherapy.

The invention belongs to the field of biological medicine, and particularly relates to a curcumin compound, a preparation method, application and a pharmaceutical composition of the curcumin compound. The curcumin compound (Cur-VE-Zn) is prepared, and the solubility of the curcumin-Zn compound can be improved and the toxicity of the curcumin-Zn compound can be reduced by adding vitamin E or a derivative thereof, so that the Cur-VE-Zn is low in cytotoxicity and good in biological safety; according to the curcumin compound disclosed by the invention, the effect of treating radiation-induced oral mucositis is achieved by removing active oxygen, relieving inflammatory response, promoting mucosal repair and reducing DNA damage. The curcumin compound is used as a main component to prepare the temperature-sensitive hydrogel, the medicine utilization rate is increased, targeted delivery of the curcumin compound in the oral mucosa is achieved, a better treatment effect is further shown, a new strategy is provided for treatment of radiation-induced oral mucositis, and the hydrogel has good application prospects.

The invention relates to the field of biomedical materials, and discloses injectable self-healing hydrogel for treating radiation-induced oral ulceration as well as a preparation method and application of the injectable self-healing hydrogel. The hydrogel provided by the invention is OCC / CDots / EGCG composite hydrogel, the OCC basic hydrogel is used as a carrier, and Vc-PEI-CDots and EGCG are loaded through a process. The composite hydrogel has an injectable characteristic, has strong antibacterial and in-vitro oxidation resistance, and has a remarkable healing promoting function. Animal experiments show that the hydrogel can effectively promote RIOM wound healing, the expression is epithelial continuous recovery, cell apoptosis reduction, and up-regulation of expression of migration promoting protein VIM and key antioxidant enzyme GPX3 in tissues, and a novel and efficient biomedical material selection is provided for treatment of clinical radiation-induced oral ulcerative mucositis.

The present invention relates to superoxide dismutase, and uses thereof for preventing or treating mucositis. The superoxide dismutase according to the present invention can be effectively used for treating or improving the inhibition of a proliferation of mucous epithelium cells, which is a side effect of anticancer agents or radiotherapy.

The invention provides application of self-gelling powder in preparation of a medicine for preventing and treating radiation-induced oral mucositis, and belongs to the technical field of medicines. The invention provides an application of self-gelling powder in preparation of a medicine for preventing and treating radiation-induced oral mucositis, the self-gelling powder is prepared from a nutgall extract and carboxymethyl chitosan through gelation, freeze drying and crushing in sequence, and the mass ratio of the nutgall extract to the carboxymethyl chitosan is (1-5): 6. The self-gel powder disclosed by the invention is good in safety and low in cost, has an excellent prevention and treatment effect on radiation-induced oral mucositis caused by head and neck radiotherapy, and can reduce the generation of inflammatory factors after radiation; the self-gel powder has a good antibacterial effect and can prevent secondary infection caused by oral mucosa injury after head and neck radiotherapy; meanwhile, the self-gelling powder becomes gel when encountering water in the oral cavity, and mechanical protection can be provided for the damaged mucous membrane surface of a patient.

The present invention relates to an aqueous liquid composition or a hydroalcoholic liquid which consists of a mixture which consists of or, alternatively, is composed of a combination of Aloe vera gel, hyaluronic acid and honey and optionally, food and / or pharmaceutical grade additives and / or technological excipients. Said composition is intended for use in the preventive and / or therapeutic treatment of symptoms and disorders associated with gastroesophageal reflux and / or laryngopharyngeal reflux (RLF) and the disease caused by it, for use as an adjuvant in the symptomatic treatment of gastroesophageal and / or laryngopharyngeal reflux, or for use in a preventive and / or therapeutic treatment against: (i) lesions of the oral cavity and the pharyngo-laryngopharyngeal tract (ii) mucositis and / or iii) aphthous ulcers and / or aphthous lesions.

The application belongs to the field of biological medicine, and particularly relates to a curcumin compound, a preparation method and use and a pharmaceutical composition thereof. The curcumin compound (Cur-VE-Zn) is prepared, wherein the addition of vitamin E or a derivative thereof can improve the solubility of the curcumin-Zn compound and reduce the toxicity of the curcumin-Zn compound, so that the Cur-VE-Zn has low cytotoxicity and good biological safety; the curcumin compound of the application can play a role in treating radiation-induced oral mucositis by eliminating active oxygen, reducing inflammatory response, promoting mucosal repair and reducing DNA damage. The application also prepares a temperature-sensitive hydrogel with the curcumin compound as a main component, improves the drug utilization rate, realizes the targeted delivery of the curcumin compound in the oral mucosa, and further exhibits better therapeutic effect, thereby providing a new strategy for the treatment of radiation-induced oral mucositis and having good application prospect.

This invention relates to the field of biomedical technology, specifically disclosing an exosome for treating radiation-induced oral mucositis and its preparation method. The exosomes are prepared from human umbilical cord mesenchymal stem cells pretreated with FC-tagged IL-11, and thalidomide is encapsulated within the exosome lumen through incubation to form HUCMSCs. FI -exo-THD. This exosome exhibits excellent biocompatibility and targeting, significantly improving the delivery efficiency and therapeutic effect of thalidomide in the treatment of radiation-induced oral mucositis. Experimental results show that, compared with free thalidomide and other single-treatment exosomes, HUCMSCs... FI -exo-THD exhibits more significant effects in restoring cell viability and inhibiting apoptosis in X-ray-induced damage to human oral mucosal epithelial cells, increasing cell viability by more than 30% and reducing the apoptosis rate to below 10%. The preparation method of this invention is simple, reproducible, and suitable for large-scale production, providing a new strategy for the clinical treatment of radiation-induced oral mucositis.

The invention discloses sound power driven Janus hydrogel as well as a preparation method and application thereof. The hydrogel comprises silver peroxide and a hydrogel matrix, the hydrogel matrix is prepared from methacrylated silk fibroin, gamma-polyglutamic acid-N-hydroxysuccinimide ester and a photoinitiator. Through component synergy and structural innovation, the prepared hydrogel can release ROS according to ultrasonic drive, destroys bacterial biofilms, and cooperates with Ag < + > slowly released by Ag2O2 to achieve an efficient sterilization effect; after the hydrogel is cross-linked by ultraviolet light, a Janus structure of which one side is adhered and the other side is anti-adhesion can be formed. Pharmacodynamic experiment results show that the sonodynamic-driven Janus hydrogel prepared by the invention has an excellent antibacterial effect, can be used for promoting wound healing, repairing alveolar bone defects and the like, and also provides a new choice for repairing infections such as periodontitis, oral mucosa inflammation and the like or skin wounds.

The invention provides a preparation method of bitter wine soup powder for treating radiation-induced oral mucositis. The preparation method comprises the following steps: a, weighing the following raw materials in parts by weight: rhizoma pinelliae preparata, egg white and rice vinegar; b, adding rice vinegar into the rhizoma pinelliae preparata, soaking, then dipping, percolating by adopting a percolation method, and collecting percolate; and c, uniformly mixing the percolate with egg white, filtering, and freeze-drying to obtain freeze-dried powder. Compared with a traditional method, the preparation method has the advantages that effective substances in pinellia ternate are fully dissolved out, and the transfer rate is higher. The preparation method is simpler, and the problems of uncontrollable egg white industrial heating quality, easy solidification and the like are avoided. Compared with a liquid form in an ancient method, the bitter wine soup powder prepared by the method disclosed by the invention is better in taste, free from fishy odor and easy to store. Compared with a bitter wine soup obtained by an ancient method, the bitter wine soup powder disclosed by the invention has a better treatment effect on RTOM.

The present invention relates to a composition for preventing, treating, or ameliorating mucositis, comprising a Lactobacillus sakei CVL-001 strain. Both live and inactivated cells of the Lactobacillus sakei CVL-001 strain exhibit an effect of alleviating symptoms related to mucositis induced by anticancer chemotherapy or radiotherapy performed to treat cancer, and can therefore be effectively used for the prevention, treatment, or amelioration of mucositis.

The present disclosure provides for compositions including GlcNAc and methods of treating or preventing oral diseases, and the like. In an aspect, GlcNAc can be used as an agent in a composition to treat and / or prevent oral diseases such as dental caries (or tooth decay), oral candidiasis (or oral thrush), periodontitis, peri-mucositis and peri-implantitis. Each of these diseases is a biofilm disease with a dysbiotic etiology.